HC Wainwright Forecasts Higher Earnings for Pharming Group

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Investment analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Pharming Group in a research note issued on Thursday, October 22nd. HC Wainwright analyst J. Pantginis now expects that the company will earn $0.45 per share for the quarter, up from their prior estimate of $0.23. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group’s current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Pharming Group’s Q4 2026 earnings at $0.00 EPS and FY2026 earnings at $0.45 EPS.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Tuesday, October 27th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.15. The firm had revenue of $117.60 million during the quarter, compared to analysts’ expectations of $117.60 million.

Several other research firms have also recently weighed in on PHAR. Wall Street Zen raised Pharming Group to a “hold” rating in a report on Saturday. Canaccord Genuity Group set a $38.00 price target on shares of Pharming Group in a research note on Wednesday, September 23rd. Zacks Research upgraded shares of Pharming Group from a “strong sell” rating to a “hold” rating in a research note on Friday, October 23rd. Weiss Ratings reissued a “sell (d)” rating on shares of Pharming Group in a research report on Friday, August 7th. Finally, Oppenheimer restated an “outperform” rating on shares of Pharming Group in a research note on Thursday, July 30th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $38.67.

Pharming Group Trading Down 0.3%

Shares of PHAR stock opened at $11.87 on Monday. The company has a 50 day moving average price of $10.69 and a 200-day moving average price of $13.89. Pharming Group has a 52 week low of $9.11 and a 52 week high of $21.34.

Institutional Trading of Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP purchased a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group makes up about 6.0% of MAC Alpha Capital Management LP’s investment portfolio, making the stock its 2nd biggest position. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group as of its most recent SEC filing. Institutional investors and hedge funds own 0.03% of the company’s stock.

Key Headlines Impacting Pharming Group

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Third-quarter revenue rose 21% year over year to $117.6 million, in line with estimates, while adjusted earnings of $0.30 per share exceeded the $0.15 consensus estimate. Operating profit increased 89% to $29.9 million. Pharming Group Reports Nine-Month Earnings Results
• Positive Sentiment: Growth was broad-based: RUCONEST revenue increased 14% to $93.8 million, while Joenja revenue jumped 58% to $23.8 million on stronger U.S. and international demand. Pharming Third-Quarter Financial Results
• Positive Sentiment: Pharming generated $32.4 million in operating cash flow during the quarter, ending with $190.9 million in cash. The company also highlighted Joenja expansion through a U.S. pediatric label and launches in Germany and Japan. Pharming Q3 Results Presentation
• Neutral Sentiment: Pharming tightened its 2026 revenue guidance to $380 million-$390 million, compared with the previous $375 million-$395 million range. The midpoint increased modestly, although the narrower range may have limited the surprise from the results. Pharming Q3 Earnings and Revenue Increase
• Neutral Sentiment: Investors are awaiting topline results from a Phase II trial of leniolisib in the broader common variable immunodeficiency population, expected in November 2026. Positive data could provide another growth catalyst, while disappointing results would create risk. Pharming Growth Ahead of CVID Data
• Neutral Sentiment: Management’s earnings call reiterated the growth strategy and discussed Joenja expansion, cash generation and the upcoming CVID readout. Reported short interest was zero as of October 26, offering no meaningful evidence of short-selling pressure. Pharming Q3 2026 Earnings Call Transcript

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.